February 17, 2026 06:22 am (IST)
Follow us:
Pharmaceuticals dept visits USP India facility in Hyderabad
Hyderabad / Kolkata, Feb 5 (IBNS): Sudhansh Pant, Joint Secretary, Department of Pharmaceuticals (DoP), visited the US Pharmacopeia's (USP) state-of-the-art India facility in Hyderabad.
He toured the facility and met with senior level scientists. The purpose of this visit was to better understand the efforts USP is making in India to create standards for medicines, ensure full safety and quality of medicines and bring to India international standards in drug manufacture.
India’s continued export growth in pharmaceuticals requires that every drug exported meets with the highest quality and safety requirements. USP is uniquely positioned to provide guidelines in this area.
USP develops the reference standards to ensure the quality of Active Pharmaceutical Ingredients (APIs) and is supportive of government initiatives to strengthen and revive the domestic manufacturing of intermediaries and APIs.
The Joint Secretary’s discussion with USP India touched upon various aspects of ensuring the quality of medicines in India and how USP standards could help Indian manufacturers to import their products both to the US and to other countries.
Pant also enquired about the verification program and process and showed interest in the education and training programs conducted by USP. He was very impressed by the state-of-the-art facility and appreciated the quality and safety aspects maintained in the facility.
KV Surendranath, Senior Vice President- International Sites Operations said, “We welcome this opportunity to showcase our technical expertise to the Department of Pharmaceuticals. We see ourselves as partners in India’s efforts to produce safe and high quality medicines that meet all global standards. We hope to continue with future engagements with the DoP on various aspects related to quality of medicines and to address issues of critical importance to patient safety.”
Sudhansh Pant commented that he was very impressed and that the visit was quite enlightening and informative. He noted the commendable work being done at the facility in the field of standards, testing and research and the various collaborations in the interest of the Indian pharmaceutical industry. Mr. Pant hopes that other governments and private institutions will benefit from the presence of USP’s world class facility in Hyderabad.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
New recombinant mpox strain detected in UK and India; WHO calls for heightened surveillance
Mon, Feb 16 2026
WHO prequalifies additional nOPV2 vaccine, strengthening global fight against polio
Fri, Feb 13 2026
Game-changer for TB patients in India: Shorter oral regimens slash costs, ICMR finds
Fri, Feb 13 2026
Global health alert: Obesity linked to 10% of all infectious disease deaths, says study
Wed, Feb 11 2026
Happy Chocolate Day: Your favourite treat comes with surprising health benefits, reveals study
Mon, Feb 09 2026
Grey matter decline, anxiety, sleep issues: What Menopause really does to your brain, study gives you the answer
Sun, Feb 08 2026
Men at risk by 35? Major study reveals early heart disease warning
Wed, Feb 04 2026